Abstract
A link between common chromosome fragile sites and frequent chromosomal deletions in cancer was observed two decades ago and led to the hypothesis that genes at fragile sites may play a role in tumor development. In 1996, the human fragile histidine triad gene, FHIT, was identified by positional cloning of the chromosome region spanning the carcinogen-sensitive, common fragile site, FRA3B at 3p14.2. Loss or inactivation of the FHIT gene in a large fraction of human tumors results in absence or reduction of Fhit protein. In vitro analyses and in vivo tumorigenicity studies show that restoration of Fhit protein induces tumor suppression in 50% of tumor cell lines tested. Viral vector-mediated FHIT gene transfer to Fhit-deficient mice not only prevents but reverses the carcinogen-induced tumor development in vivo, in accordance with the oncosuppressive properties of Fhit protein. The strong proapoptotic activity following Fhit infection of cancer cells strengthens the case for further exploration of FHIT gene therapy in cancer prevention and treatment.
Keywords: chromosome, FRA3B, protein, proapoptotic, carcinogen
Current Gene Therapy
Title: Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses
Volume: 4 Issue: 1
Author(s): Hideshi Ishii, Andrea Vecchione, Louise Y.Y. Fong, Nicola Zanesi, Francesco Trapasso, Yusuke Furukawa, Raffaele Baffa, Kay Huebner and Carlo M. Croce
Affiliation:
Keywords: chromosome, FRA3B, protein, proapoptotic, carcinogen
Abstract: A link between common chromosome fragile sites and frequent chromosomal deletions in cancer was observed two decades ago and led to the hypothesis that genes at fragile sites may play a role in tumor development. In 1996, the human fragile histidine triad gene, FHIT, was identified by positional cloning of the chromosome region spanning the carcinogen-sensitive, common fragile site, FRA3B at 3p14.2. Loss or inactivation of the FHIT gene in a large fraction of human tumors results in absence or reduction of Fhit protein. In vitro analyses and in vivo tumorigenicity studies show that restoration of Fhit protein induces tumor suppression in 50% of tumor cell lines tested. Viral vector-mediated FHIT gene transfer to Fhit-deficient mice not only prevents but reverses the carcinogen-induced tumor development in vivo, in accordance with the oncosuppressive properties of Fhit protein. The strong proapoptotic activity following Fhit infection of cancer cells strengthens the case for further exploration of FHIT gene therapy in cancer prevention and treatment.
Export Options
About this article
Cite this article as:
Ishii Hideshi, Vecchione Andrea, Fong Y.Y. Louise, Zanesi Nicola, Trapasso Francesco, Furukawa Yusuke, Baffa Raffaele, Huebner Kay and Croce M. Carlo, Cancer Prevention and Therapy in a Preclinical Mouse Model: Impact of FHIT Viruses, Current Gene Therapy 2004; 4 (1) . https://dx.doi.org/10.2174/1566523044578031
DOI https://dx.doi.org/10.2174/1566523044578031 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 6
Current Topics in Medicinal Chemistry Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Current Medicinal Chemistry Overview of Coumarins and its Derivatives: Synthesis and Biological Activity
Letters in Organic Chemistry Cranberry for Urinary Tract Infection: From Bench to Bedside
Current Topics in Medicinal Chemistry Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry Mitochondria-targeted Resveratrol Derivatives Act as Cytotoxic Pro-oxidants
Current Pharmaceutical Design The Potential Protective Effect of Orange Peel and Selenium against 17β-Estradiol- Induced Chronic Non-Bacterial Prostatitis in Rats
Anti-Cancer Agents in Medicinal Chemistry The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine Intravesical Therapy of Superficial Bladder Cancer
Current Pharmaceutical Design Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology Synthesis and Applications of Nanoflowers
Recent Patents on Nanotechnology Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
Current Pharmaceutical Design Network Medicine and High Throughput Screening
Current Drug Discovery Technologies Characterization of Breast Lesions by Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS)
Current Medical Imaging Insulin-like Effects of Mt. Fuji Subsoil Water which Conta ins Vanadium on Cultured Cells: Insight from Japan
Current Traditional Medicine The Use of Mathematical Modelling for Improving the Tissue Engineering of Organs and Stem Cell Therapy
Current Stem Cell Research & Therapy